Page 3 - மையக் காட்சி கூட்டாளர்கள் ஒன்றுபட்டது கிஂக்டம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மையக் காட்சி கூட்டாளர்கள் ஒன்றுபட்டது கிஂக்டம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மையக் காட்சி கூட்டாளர்கள் ஒன்றுபட்டது கிஂக்டம் Today - Breaking & Trending Today

AstraZeneca to buy Boston biotech Alexion for $39 billion in rare-disease push

AstraZeneca to buy Boston biotech Alexion for $39 billion in rare-disease push
By John Lauerman Bloomberg,Updated December 12, 2020, 10:01 a.m.
Email to a Friend
AstraZeneca s facilities in Sodertalje, Sweden. The company agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares on Dec. 12, 2020.Mikael Sjoberg/Bloomberg
(Bloomberg) AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in treatments for rare diseases and immunology to its portfolio of medications for cancer and other illnesses.
The offer values Alexion at $175 a share, a 45 percent premium to the closing price on Friday. It would be the largest deal for AstraZeneca since it was founded in a combination of British and Swedish drugmakers in 1999. ....

United States , Alexion Soliris , Elliott Management Corp , Morgan Stanley , Regeneron Pharmaceuticals Inc , Goldman Sachs Group Inc , Gilead Sciences Inc , America Corp , Eli Lilly Co , Evercore Partners International , Portola Pharmaceuticals , Jpmorgan Chase Co , Centerview Partners United Kingdom , Pfizer Inc , Eli Lilly , Regeneron Pharmaceuticals , Elliott Management , Zeneca American Depositary Shares , Goldman Sachs Group , ஒன்றுபட்டது மாநிலங்களில் , எலியட் மேலாண்மை கார்ப் , மோர்கன் ஸ்டான்லி , கோல்ட்மேன் சாக்ஸ் குழு இன்க் , கிலியட் அறிவியல் இன்க் , அமெரிக்கா கார்ப் , எலி லில்லி இணை ,

AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push

AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push
Bloomberg
12/13/2020
(Bloomberg)
AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc.
The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, U.K.-based AstraZeneca, which had spent years paring away older and less profitable products to focus on cancer.
While the pandemic smothered economies and AstraZeneca entered a relatively low-return project to develop a Covid-19 vaccine with the University of Oxford, Chief Executive Officer Pascal Soriot kept his eyes downfield. After months of patients avoiding hospitals and clinics for fear of viral exposure, immunizations are coming online that promise to return society, and the drug industry, to some s ....

United States , United Kingdom , Geoffrey Porges , Marc Dunoyer , Pascal Soriot , Morgan Stanley , Goldman Sachs Group Inc , Astrazeneca Plc , Gilead Sciences Inc , Eli Lilly Co , Jpmorgan Chase Co , Pfizer Inc , Elliott Management Corp , Regeneron Pharmaceuticals Inc , University Of Oxford , Alexion Pharmaceuticals Inc , America Corp , Evercore Partners International , Portola Pharmaceuticals , Centerview Partners United Kingdom , Zeneca Plc , Alexion Pharmaceuticals , Chief Executive Officer Pascal Soriot , Eli Lilly , Regeneron Pharmaceuticals , Elliott Management ,

Näringsliv Börs

12 december 2020 kl 13:59
Greater scientific presence in immunology by adding Alexion s innovative complement-technology platforms and strong pipeline
Dedicated rare disease unit to be headquartered in Boston
Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care
Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca s broad-based revenue and the company will further globalise Alexion s portfolio
Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend
The acquisition will be immediately core earnings-accretive andvalue-enhancing, and is aligned with stated capital-allocation priorities
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. ....

United States , United Kingdom , City Of , Astrazeneca Adss , Rosen Katz , Ludwig Hantson , Chris Stevo , Freshfields Bruckhaus Deringer , Pascal Soriot , Tanisha Carino , Jp Morgan Cazenove , Ellen Chiniara , Megan Goulart , Brian Goff , Indrani Franchini , Morgan Stanley , Company On Twitter , Prudential Regulation Authority , Goldman Sachs , York State Department Of Financial Services , Morgan Stanley Bank International , Goldman Sachs International , Neither Goldman Sachs International , Morgan Stanley Co , London Stock Exchange , Goldman Sachs Bank United States ,

AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development

Press release content from Business Wire. The AP news staff was not involved in its creation.
AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development
December 12, 2020 GMT
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Dec 12, 2020
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. ....

United States , United Kingdom , City Of , Astrazeneca Adss , Rosen Katz , Ludwig Hantson , Chris Stevo , Freshfields Bruckhaus Deringer , Pascal Soriot , Tanisha Carino , Jp Morgan Cazenove , Ellen Chiniara , Megan Goulart , Brian Goff , Indrani Franchini , Adrian Kemp , Morgan Stanley , Prudential Regulation Authority , Goldman Sachs , York State Department Of Financial Services , Morgan Stanley Bank International , Goldman Sachs International , Company On Twitter Astrazeneca , Neither Goldman Sachs International , Morgan Stanley Co , London Stock Exchange ,